BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2026 9:45:10 AM | Browse: 4 | Download: 0
 |
Received |
|
2026-01-12 05:31 |
|
Peer-Review Started |
|
2026-01-12 05:31 |
|
First Decision by Editorial Office Director |
|
2026-01-20 07:57 |
|
Return for Revision |
|
2026-01-20 07:57 |
|
Revised |
|
2026-01-21 12:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-28 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-28 04:20 |
|
Articles in Press |
|
2026-01-28 04:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-08-18 00:31 |
|
Publish the Manuscript Online |
|
2026-09-09 09:45 |
| ISSN |
1948-5204 (online) |
| Open Access |
The first time an abbreviation appears in the manuscript, please label it with its full name. |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Opinion Review |
| Article Title |
Rethinking the timing of adjuvant chemotherapy in advanced gastric cancer: From feasibility to precision sequencing
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Qiong Zhou and Qing-Hua Ke |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qing-Hua Ke, Chief Physician, PhD, Department of Chemoradiotherapy, Jingzhou No. 1 People's Hospital and First Affiliated Hospital of Yangtze University, No. 10 Tianhu Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com |
| Key Words |
Adjuvant chemotherapy; Gastric cancer; Timing of chemotherapy; Precision oncology; Peritoneal recurrence |
| Core Tip |
The optimal timing for adjuvant chemotherapy (AC) in gastric cancer (GC) is undefined. Lin et al's study demonstrates that ultra-early AC (10-13 days post-surgery) is feasible and safe under Enhanced Recovery After Surgery protocols, with a signal for reduced peritoneal recurrence but no survival advantage. The study's limitations, including a lack of molecular profiling and small sample size, underscore the need for a more sophisticated approach. We propose a "precision timing" framework that integrates tumor biology (e.g., molecular subtypes, circulating tumor DNA), patient recovery, and dynamic monitoring to guide AC initiation. This shift from a traditional feasibility paradigm to biomarker-driven, individualized sequencing holds the key to improving outcomes in high-risk GC. |
| Publish Date |
2026-09-09 09:45 |
| Citation |
Zhou SQ, Ke QH. Rethinking the timing of adjuvant chemotherapy in advanced gastric cancer: From feasibility to precision sequencing. World J Gastrointest Oncol 2026; 18(9): 118773
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i9/118773.htm |
| DOI |
https://doi.org/10.4251/wjgo.118773 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
